Home
Country selector

ATM Targeting

DNA Damage Response (DDR)

ATM targeting

ATM mutations occur frequently in cancer cells. Inherited ATM deficiency leads to ataxia–telangiectasia, a genome instability syndrome characterized by neurodegeneration, immunodeficiency, radiation sensitivity, and cancer susceptibility. Thus, ATM has a clear role in the maintenance of genome stability, cellular and tissue functioning, and cancer prevention.1,2

Upon detection of a double-stranded break (DSB), ATM is recruited to the break site. Following activation, ATM triggers a signaling cascade resulting in cell cycle arrest and DSB repair. It can also trigger apoptosis or senescence if necessary.3-5

M4076

M4076 is an investigational, orally administered, selective ATP-competitive ATM inhibitor. ATM activity is dispensable for cellular viability, yet necessary for maintaining genome integrity. It plays a pivotal role in DNA DSB signaling and repair.3-5

DDRiver Solid Tumors 4106 (NCT04882917)

A Phase 1, open-label trial evaluating M4076 in patients with advanced solid tumors.

DDRiver

Are you interested in learning more about a clinical trial program investigating the potential anticancer effect of inhibiting the DDR pathway?

Learn about DDRiver clinical trials
Other targets under investigation

This investigational compound has not been approved by any health authority. Safety and efficacy have not been established.

ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia RAD3-related; DDR, DNA damage response; DSB, double-stranded break.

  1. Macheret M, Halazonetis TD. DNA replication stress as a hallmark of cancer. Annu Rev Pathol. 2015;10:425-448. 
  2. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer. 2003;3(3):155-168. 
  3. Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell. 2017;66(6):801-817. 
  4. Carrassa L, Damia G. DNA damage response inhibitors: mechanisms and potential applications in cancer therapy. Cancer Treat Rev. 2017;60:139-151. 
  5. Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med. 2015;66:129-143 
  6. First-in-human study of M4076 in advanced solid tumors (DDRiver Solid Tumors 410). ClinicalTrials.gov identifier: NCT04882917. Updated July 20, 2023. Accessed December 1, 2023. https://clinicaltrials.gov/ct2/show/NCT04882917

GL-MULO-00159 | December 2023

This website is an international information resource intended only for Healthcare Professionals who are licensed to practice outside the U.S., Canada, and Puerto Rico.

The information on this site is intended for educational purposes.

Connect with us

Find the Healthcare Business of Merck on:

©2024 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved. Registered address: Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany

GL-MULO-00155 | November 2023

Cookie Disclaimer

We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the website and to manage our corporate commercial objectives, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide which categories you would like to permit. Please note that depending on the settings you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy.

ACCEPT COOKIES
Your settings for the cookies

These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.

In order to continuously improve our website, we anonymously track data for statistical and analytical purposes. With these cookies we can, for example, track the number of visits or the impact of specific pages of our web presence and therefore optimize our content. 

These cookies allow us to provide more comfort for you. For example, previously searched products or services can be reloaded again after revisiting our website and you won’t need to enter all the details again. We can also detect if you need assistance with using our website and therefore offer you direct customer support.

These cookies are used to display personalized content matching your interests. We can display personalized and relevant services to ensure you are always up to date on related offers.

By clicking this link, you are leaving MerckGroupOncology.com. Please, note that this link will take you to a website оn which different Privacy Policy and Conditions may apply. Merck accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Continue
Go Back

Welcome to Merck Healthcare!

Help us direct you to the right information by selecting one of the following options:

I'm a Healthcare Professional

I'm NOT a Healthcare Professional